PSC to enter US injectables space with new CMO at former PurTox site

By Gareth Macdonald

- Last updated on GMT

Related tags Pharmacology

PSC to enter US injectables space with new CMO unit
PSC Biotech plans to enter the US sterile injectables contracting space after buying a plant originally set up by J&J unit Mentor Biologics to make a Botox rival.

California based IT and professional services firm PSC said it would set up BioTechnique last week, explaining that the contractor will be based at a site in Madison, Wisconsin recently acquired from the Morgridge Institute for Research.

The 37,000 square foot facility at Madison University’s Research Park was built by Mentor Biologics in 2008, which intended to use the facility to make a botulin-toxin product, PurTox in a bid to capture market share from Botox.

This plan was shelved in 2010 after Mentor was bought by US drug giant Johnson and Johnson,​ which decided it could make PurTox using existing capacity. The facility – worth an estimated $16m – was subsequently donated to the Morgridge Institute.

Raphi Hanessian, managing director of PSC Biotech’s investment wing, said the facility will “help meet the high demand for cytotoxic and high potency fill-finish contract manufacturing services of sterile injectable products​.”

According to PSC, BioTechnique will provide the pharmaceutical industry with specialized filling services for cytotoxic, high potency, biologic, and other sterile injectable drugs when fully operation in 2015.

Injectables trends

US sterile injectables capacity has been struggling to meet demand since Ben Venue first halted and then abandoned manufacturing operations in 2011 after a number of quality problems at its site in Ohio.

The failure of Ben Venue – recently sold to Hikma​ by Boehringer Ingelheim – resulted in drug shortages, notably of J&J’s ovarian cancer treatment Doxil​, and prompted law changes​ on both sides of the Atlantic requiring drugmakers to report potential supply disruptions.

In the years since the a number of firms in the contract manufacturing sector have invested in sterile injectables manufacturing capacity with – before Hikma – DPT​ and AMRI​ being the most recent examples.

The fallout of the Ben Venue problems has also seen some manufacturers decide to take production back in-house​, examples of which include Pfizer and Sun pharma​ which recently acquired InnoPharma and Pharmalucence, respectively.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us


View more